Organoids are exciting models that are rapidly becoming a hopeful platform for many medical advances such as drug screening and disease modeling. However, due to a lack of vascularization, they have limitations for future applications. This review blog summarizes several practical methods for successful organoid vascularization to date.
Complex 3D liver models that more closely mimic human biology open opportunities for improved drug and vaccine discovery for malaria and related parasitic diseases.
Despite advances in research, around 90% of drugs fail during phase 1 clinical trials. New drugs for the treatment of cardiovascular disease and oncology have a particularly high failure rate, largely attributed to cardiotoxicity...
Implantable endoderm organoids combine synthetic support structures and cells to repair or replace the function of endoderm-derived organs like the pancreas, liver, colon, stomach, intestines, lungs, and gall bladder. Adult cells are notoriously difficult to expand in vitro without loss of function, so many implants have harnessed new technologies based on induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs). Pioneers in the field are working to optimize cell lines and effectively scale manufacture protocols to transition to the clinic and fulfill the promise of these next generation of stem cell therapies.
Qkine has concluded a sales distribution agreement with Japanese company, MBL Medical & Biological Laboratories Co., Ltd. MBL have extensive knowledge and presence within the Japanese regenerative medicine and iPSC sector, an important market for Qkine's high purity, animal-free optimised growth factor and cytokine proteins. The two companies share a focus on product quality and the emerging areas of organoid and organ-on-chip technologies for basic research, personalised medicine and drug discovery. This distributor agreement between Qkine and MBL will facilitate access to Qkine's entire range of premium quality, animal-free and novel optimised growth factor proteins across Japan.
Can Super Scientist give you your organoid mojo back? Are your growth factors the reason your experiments fail? Can you use engineered or niche-specific growth factors to improve your organoid culture? Super Scientist flies in with easy fixes and questions to ask yourself - do you need to ditch the conditioned media, play around with growth factor combinations, switch noggin and gremlin, or be bold and explore new engineered proteins.
Qkine, Manchester BIOGEL and Cellesce have been awarded Innovate UK Sustainable Innovation Funding to develop fully synthetic, chemically-defined three-dimensional (3D) scaffolds to enable manufacture scale up and improve reproducibility of patient-derived organoids.
Organoid Q&A with industry experts from the HUB, CSHL and Stemnovate We recently held a webinar with CytoSMART and organoid pioneers from Cold Spring Harbor Laboratory, Stemnovate and the Hubrecht Organoid Technology titled: what's needed to realize the potential of organoids? Following presentations from our speakers, we held an insightful [...]
On-demand webinar: What’s needed to realise the potential of organoids? From standardization of imaging techniques, to more reproducible and cost-effective organoid culture media Organoids have the potential to revolutionize current drug discovery approaches, enhance the physiological relevance of in vitro disease models, and deliver on the promise of precision medicine. But, [...]
We were delighted to be awarded Innovate UK funding to address issues of quality and availability of growth factors for use in organoid technologies. The Qkine R&D team are applying a combination of protein expression, refolding optimisation and structure-guided protein engineering to improve the biological properties and quality of proteins such as R-spondins, TGFβ1, members of the BMP and FGF family proteins.
© 2024 Qkine Ltd. Company number 10470662 registered in England and Wales. All rights reserved
